IMMUCELL CORP /DE/ 8-K

What Happened ImmuCell Corporation filed a Form 8-K on July 9, 2026 to announce preliminary, unaudited product sales for the quarter ended June 30, 2026. The company reported an 11.5% increase in product sales in Q2 2026 compared with Q2 2025 and issued a press release on the same date.

Key Details

• Reported increase: product sales up 11.5% in Q2 2026 vs Q2 2025 (preliminary, unaudited).
• Filing date and period: press release issued July 9, 2026 for the quarter ended June 30, 2026.
• Disclosure form: announcement made in a Form 8-K (Item 2.02); the press release is attached as Exhibit 99.1.
• The company notes the sales figures are preliminary and unaudited; the disclosure is not deemed "filed" under Section 18 of the Exchange Act.

Why It Matters An 11.5% year-over-year increase in product sales signals revenue growth momentum for the quarter, which is a primary driver of short-term performance for a commercial-stage company like ImmuCell. Because the figures are preliminary and unaudited, investors should watch for the company’s next quarterly report or audited filings for confirmed results and additional financial details.